Search results
Scientists restore brain cells impaired by a rare genetic disorder
NPR· 23 hours agoIn 1985, Zoghbi left her practice as a child neurologist to do research because "we could offer...
Ayala: San Antonio ‘it’ couple tells story of special needs child
San Antonio Express-News· 5 days agoIt’s been a huge week for Cruz and Olivia Ortiz. For the last three nights, they’ve reigned over “Cornyation 2024: The Court of Peripheral Opulence" as King Anchovy and his majesty’s “Snatched ...
These 2 ‘Strong Buy’ Penny Stocks Could Rally to $9, Says Piper Sandler
TipRanks via Yahoo Finance· 2 days ago‘Audentes Fortuna iuvat,’ wrote Virgil in his classic epic, the Aeneid. The saying, translated as...
Psychedelic Tx: What Meaningful Informed Consent Looks Like
Medscape· 1 day agoA psychedelic renaissance is underway in psychiatric medicine, with a growing number of studies...
Apple upgraded, Tesla downgraded: Wall Street's top analyst calls
The Fly via Yahoo Finance· 2 days agoLeerink initiated coverage of Neurogene (NGNE) with an Outperform rating and $46 price target. The...
AVXL INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Anavex Life Sciences Corp....
Benzinga· 6 days agoNEW YORK, April 25, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against
Spanberger endorses Leslie Mehta in 1st District congressional race
Richmond Times-Dispatch· 4 days agoMehta, 47, a former civil rights attorney in Chesterfield County, is running against former New Kent...
AVXL INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Anavex Life Sciences...
Morningstar· 6 days agoSAN DIEGO, April 24, 2024 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Anavex Life Sciences Corporation (NASDAQ: AVXL) stock between February 1, 2022 and January 1, 2024, inclusive (the “Class Period
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Receives $35.82 Average PT from Analysts
ETF DAILY NEWS· 1 day agoShares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Get Free Report) have been given a consensus rating of “Moderate Buy” by the fifteen brokerages that are currently covering the stock, Marketbeat.com ...
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit...
Morningstar· 7 days agoLOS ANGELES, April 24, 2024 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming May 13, 2024 deadline to file a lead plaintiff motion in the class action ...